ライフサイエンスコーパス: photophobia

1 in mice as a measure of migraine-associated photophobia.

2 ement as well as reduction of both glare and photophobia.

3 decreased visual quality marked by glare and photophobia.

4 n body sensation, conjunctival hyperemia and photophobia.

5 rgins and also moderate dry eyes with severe photophobia.

6 for sleep disorders and migraine-associated photophobia.

7 void confounding effects of illumination and photophobia.

8 provide a neural substrate for migraine-type photophobia.

9 g head pain and associated symptoms, such as photophobia.

10 s for migraine and other disorders involving photophobia.

11 ral visual impairment (CVI) often experience photophobia.

12 olors, impaired visual acuity, nystagmus and photophobia.

13 had ocular involvement, with 65% describing photophobia.

14 we noted transient headaches (11 patients), photophobia (11 patients), reduction in serum HDL concen

15 58%] of 353 vs 126 [37%] of 342 [p<0.0001]), photophobia (180 [51%] of 353 vs 99 [29%] of 342 [p<0.00

16 , with the greatest differences observed for photophobia (70% versus 6%), poor balance (63% versus 4%

17 ache relief 2 hours after dosing, absence of photophobia, absence of phonophobia, and absence of naus

18 ed visual acuity, nystagmus, strabismus, and photophobia, although pigmentation of skin and hair is r

19 ter surgery 12 patients (75.00%) reported no photophobia and 10 patients (62.50%) reported no glare.

20 This behavior appears to be an indicator of photophobia and cannot be fully explained by gross abnor

21 Transient photophobia and discomfort were common.

22 Photophobia and glare improved in every case except for

23 The other symptoms include tearing, photophobia and leukokoria.

24 ying protein 1 (RAMP1), can be a modifier of photophobia and, by extension, suggest that genetic or e

25 acterized by the clinical triad of epiphora, photophobia, and blepharospasm; increased intraocular pr

26 ecessive trait, characterized by low vision, photophobia, and lack of color discrimination.

27 l vision and subsequently night vision, mild photophobia, and moderate to high myopia.

28 ontaneous photopsia, self-light of the eye), photophobia, and nyctalopia (impaired night vision); and

29 colors, impaired visual acuity in daylight, photophobia, and nystagmus.

30 changes may result in reduced visual acuity, photophobia, and ocular irritation, though these symptom

31 ce, and migraine symptoms, such as headache, photophobia, and phonophobia, is a requisite diagnostic

32 omes were non-inferiority at 2 h for nausea, photophobia, and phonophobia.

33 Non-inferiority was shown for nausea, photophobia, and phonophobia.

34 arring alopecia, slightly runted growth, and photophobia arose at The Jackson Laboratory in 1993 in t

35 and study 2, 57% vs 29%; P<.001), absence of photophobia at 2 hours (58% vs 26%; P<.001 and 50% vs 32

36 eriphery of the mouse to cause migraine-like photophobia by apparently distinct mechanisms.

37 Here, we establish a genetic model of photophobia by engineering increased sensitivity to CGRP

38 Ocular side effects such as photophobia, cataracts, glaucoma, retinopathy, and other

39 atients' experience with colour and migraine photophobia could originate in cone-driven retinal pathw

40 The clinical phenotype was typical CORD with photophobia, decreased central vision, and dyschromatops

41 olecular targets for selective prevention of photophobia during migraine.

42 Most subjects reported moderate photophobia for 2 to 3 days after SLT; only 1 received a

43 The disease presents with a triad of photophobia, loss of color vision and reduced central vi

44 utosomal recessive disorder characterized by photophobia, low visual acuity, nystagmus and a total in

45 Recent studies demonstrated a photophobia mechanism with modulation of nociceptive, co

46 17; 39%), followed by tearing (n = 10; 23%), photophobia (n = 6; 14%), itching (n = 4; 9%), swelling

47 e disorder characterized by color blindness, photophobia, nystagmus and severely reduced visual acuit

48 y alterations in sensory perception, such as photophobia or allodynia, which have in common an uncomf

49 he authors find an effect on the OAER due to photophobia or eye color.

50 chal rigidity, altered cutaneous sensations, photophobia, or visual disturbances.

51 consist of blurred vision, redness, tearing, photophobia, pain and foreign body sensation.

52 ing, foreign body sensation, eye discomfort, photophobia, pain), ocular discomfort score (ODS), and s

53 Fifteen eyes (83%) had photophobia, pain, or both.

54 to understand better the neural substrate of photophobia paved a way to the development of different

55 s reported so far include: headaches, severe photophobia, persistent foreign body sensation, and migr

56 ere pain freedom, pain relief, or absence of photophobia, phonophobia, or nausea at 2 h after treatme

57 A 34 year old male presented with pain, photophobia, redness and decreased vision in his right e

58 characterized by reduced visual acuity, mild photophobia, reduced amplitude of the cone electroretino

59 with variable degrees of night blindness or photophobia, reduced visual acuity, high myopia, and nys

60 The visual acuity, subjective glare and photophobia reduction, anatomic outcome, and complicatio

61 ar-old child with cyst recurrence and severe photophobia requiring resection.

62 a or vomiting, fever, weight loss, headache, photophobia, seizure, extremity weakness, or sensory dis

63 defects, cleft palate, extradural cysts, and photophobia, suggesting a defect in a gene with pleiotro

64 ary measures include reduction in nausea and photophobia, use of rescue medication, relapse of headac

65 ptoms including nausea, unilateral location, photophobia, visual disturbance, and numbness.

66 Historically, photophobia was studied in patients and attempts to expl

67 Nausea and photophobia were significantly reduced (P=.03 and P=.001

68 We have focused on the role of CGRP in photophobia, which is a common migraine symptom.

69 ich was unilateral in 14 (48%); 29 (74%) had photophobia, which was unilateral in 14 (48%); and 27 (6